Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a phase I study of the safety, tolerability, pharmacokinetics profile, and
preliminary efficacy of TT-00434 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
TransThera Biosciences Co., Ltd TransThera Sciences (Nanjing), Inc.